ARID1A and neoplasm: There was no significant association between HRR gene status in ctDNA and clinical outcome, However, our results indicate that ctDNA analysis may be feasible for biomarker selection in clinical trials (i.e. oncogenic ARID1A detected in 20% of blood samples), as suggested by the significant association of archival tumour mutations and ctDNA.